Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension

Sychev D.A.1, Shih N.V.2 , Kalle E.G.1, Ryzhikova K.A.1, Morozova T.E.2

1. Russian Medical Academy of Continuing Professional Education, Moscow, Russia
2. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
Section: Technologies of Precision Medicine
DOI: 10.18097/PBMC20176305432      PubMed Id: 29080877
Year: 2017  Volume: 63  Issue: 5  Pages: 432-439
An open, non-comparative, prospective clinical study was conducted to evaluate the antihypertensive efficacy and tolerability of amlodipine, a calcium antagonist, in patients with arterial hypertension (AH) I-II stages, depending on the genotype for the polymorphic marker C3435T of the ABCB1 gene. The study included 100 patients with AH I-II stages, aged from 45 to 58 years. The initial dose of amlodipine was 5 mg, duration of treatment was 12 weeks. General clinical examination methods, office measurement and daily blood pressure monitoring, tolerance evaluation, and genotyping using the ABCB1 polymorphic marker C3435T by the PCR-RFLP method (polymerase chain reaction and restriction fragment length polymorphism) were used. The statistical analysis of results was carried out using the Mann-Whitney U test for quantitative variables, Kruskal-Wallis one-way analysis of variance (ANOVA) for three independent groups of quantitative data. Excellent antihypertensive efficacy with the CC genotype was found in 11.8% patients, with CT – 33.9%, with TT – 43.3%; good – 35.3%, 32.1%, and 33.3% respectively, satisfactory – 52.9%, 34,0% and 23.4% respectively. Six patients with the CT genotype and nine patients with the CC genotype required the increase in the dose to 10 mg. The number of patients with Adverse drug reactions (ADR) were found in 35.3% of patients with the CC genotype, 6.7% with the TT genotype and 11.3% with the CT genotype. The Kruskal-Wallis test revealed significant differences between CC and TT genotypes in the degree of decrease in SBP (p=0.02), antihypertensive efficacy parameter (p=0.02), an increase in dose requirements (p = 0.04) and the incidence of ADR(p=0.05). In AH patients (I-II stage) with the TT genotype of the C3435T gene polymorphism one can expect higher rates of antihypertensive efficacy of amlodipine in combination with a good safety profile and the lowest ADR percentage, while patients with the CC genotype more likely to develop ADR and lower antihypertensive responsiveness.
Download PDF:  
Keywords: pharmacogenetics, ABCB1 gene, gene polymorphism, arterial hypertension, amlodipine

Sychev, D. A., Shih, N. V., Kalle, E. G., Ryzhikova, K. A., Morozova, T. E. (2017). Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension. Biomeditsinskaya Khimiya, 63(5), 432-439.
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)